Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU) — PVAIN  

Pulmonary Infections Clinical Trial

Official title: Pilot Study of Dornase Alfa (Pulmozyme) Therapy for Acquired Ventilator Associated Infection in Preterm and Late Preterm Infants in the Neonatal Intensive Care Unit

Status Completed

Clinical Trial Summary

To evaluate the effect of Dornase alfa on preterm and late preterm neonates with ventilator associated pulmonary infections. Dornase alfa has been effective in the treatment of pulmonary infections in patients with cystic fibrosis by aiding mucus clearance. The bacteria causing pulmonary infections in cystic fibrosis patients is similar to those infecting preterm infants. The investigators expect that dornase alfa therapy will improve recovery from ventilator associated pulmonary infections in preterm infants.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Pulmonary Infections

• NCT number: NCT01356147
• Study type: Interventional
• Source: Georgetown University
• Status: Completed
• Phase: Phase 4
• Start date: May 2011
• Completion date: April 30, 2017